164 related articles for article (PubMed ID: 30401688)
1. Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.
George DJ; Martini JF; Staehler M; Motzer RJ; Magheli A; Donskov F; Escudier B; Li S; Casey M; Valota O; Laguerre B; Pantuck AJ; Pandha HS; Patel A; Lechuga M; Ravaud A
Clin Cancer Res; 2019 Feb; 25(4):1165-1173. PubMed ID: 30401688
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
[TBL] [Abstract][Full Text] [Related]
3. Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.
Rini BI; Escudier B; Martini JF; Magheli A; Svedman C; Lopatin M; Knezevic D; Goddard AD; Febbo PG; Li R; Lin X; Valota O; Staehler M; Motzer RJ; Ravaud A
Clin Cancer Res; 2018 Sep; 24(18):4407-4415. PubMed ID: 29773662
[No Abstract] [Full Text] [Related]
4. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients.
Liu X; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Oncotarget; 2017 Jan; 8(1):1204-1212. PubMed ID: 27901483
[TBL] [Abstract][Full Text] [Related]
6. Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.
George DJ; Martini JF; Staehler M; Motzer RJ; Magheli A; Escudier B; Gerletti P; Li S; Casey M; Laguerre B; Pandha HS; Pantuck AJ; Patel A; Lechuga MJ; Ravaud A
Clin Cancer Res; 2018 Apr; 24(7):1554-1561. PubMed ID: 29374054
[No Abstract] [Full Text] [Related]
7. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
Beuselinck B; Jean-Baptiste J; Schöffski P; Couchy G; Meiller C; Rolland F; Allory Y; Joniau S; Verkarre V; Elaidi R; Lerut E; Roskams T; Patard JJ; Oudard S; Méjean A; Lambrechts D; Zucman-Rossi J
BJU Int; 2016 Dec; 118(6):890-901. PubMed ID: 27417418
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.
Patel A; Ravaud A; Motzer RJ; Pantuck AJ; Staehler M; Escudier B; Martini JF; Lechuga M; Lin X; George DJ
Clin Cancer Res; 2020 Sep; 26(18):4863-4868. PubMed ID: 32546645
[TBL] [Abstract][Full Text] [Related]
9. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
10. Association between age and sex and mortality after adjuvant therapy for renal cancer.
Mamtani R; Wang XV; Gyawali B; DiPaola RS; Epperson CN; Haas NB; Dutcher JP
Cancer; 2019 May; 125(10):1637-1644. PubMed ID: 30620389
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients.
Dornbusch J; Walter M; Gottschalk A; Obaje A; Junker K; Ohlmann CH; Meinhardt M; Zacharis A; Zastrow S; Schoffer O; Grimm MO; Klug SJ; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Jun; 142(6):1171-82. PubMed ID: 26935927
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.
Ravaud A; Motzer RJ; Pandha HS; George DJ; Pantuck AJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Martini JF; Ramaswamy K; Casey M; Staehler M; Patard JJ;
N Engl J Med; 2016 Dec; 375(23):2246-2254. PubMed ID: 27718781
[TBL] [Abstract][Full Text] [Related]
13. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.
Staehler M; Motzer RJ; George DJ; Pandha HS; Donskov F; Escudier B; Pantuck AJ; Patel A; DeAnnuntis L; Bhattacharyya H; Ramaswamy K; Zanotti G; Lin X; Lechuga M; Serfass L; Paty J; Ravaud A
Ann Oncol; 2018 Oct; 29(10):2098-2104. PubMed ID: 30412222
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.
Vanmechelen M; Lambrechts D; Van Brussel T; Verbiest A; Couchy G; Schöffski P; Dumez H; Debruyne PR; Lerut E; Machiels JP; Richard V; Albersen M; Verschaeve V; Oudard S; Méjean A; Wolter P; Zucman-Rossi J; Beuselinck B
Clin Genitourin Cancer; 2019 Apr; 17(2):e235-e246. PubMed ID: 30527746
[TBL] [Abstract][Full Text] [Related]
16. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Motzer RJ; Haas NB; Donskov F; Gross-Goupil M; Varlamov S; Kopyltsov E; Lee JL; Melichar B; Rini BI; Choueiri TK; Zemanova M; Wood LA; Reaume MN; Stenzl A; Chowdhury S; Lim HY; McDermott R; Michael A; Bao W; Carrasco-Alfonso MJ; Aimone P; Voi M; Doehn C; Russo P; Sternberg CN;
J Clin Oncol; 2017 Dec; 35(35):3916-3923. PubMed ID: 28902533
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
18. Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial.
Zhao F; Cella D; Manola J; DiPaola RS; Wagner LI; Haas NSB
Support Care Cancer; 2018 Jun; 26(6):1889-1895. PubMed ID: 29274030
[TBL] [Abstract][Full Text] [Related]
19. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy after nephrectomy for renal cell carcinoma.
Ravaud A
Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():33-36. PubMed ID: 30489037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
